The Role Of Oligodendrocytes In Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$625,292.00
Summary
Dementia affects 35.6 million people world-wide; this number is projected to double every 20 years. Frontotemporal dementia (FTD) is the second most common type and has been found to have similar cause and pathology to common neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). We ultimately require treatments to slow, stop and repair the damaged brain of FTD patients and this is only possible by understanding the mechanisms involved in the onset and progression of disease.
Optimising Speech Assessment And Treatment In Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$722,210.00
Summary
Frontotemporal dementia has a devastating impact on our ability to speak and understand others. This proposal aims to improve our understanding of how to best assess, diagnose and treat these debilitating impairments. By bringing together an international consortium of clinics, these findings will lead to significant advances in our understanding of disease progression and patient care.